Laboratory Corp. of America Holdings (NYSE:LH) SVP Der Vaart Sandra D. Van Sells 208 Shares of Stock

Laboratory Corp. of America Holdings (NYSE:LH) SVP Der Vaart Sandra D. Van sold 208 shares of the company’s stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $188.49, for a total transaction of $39,205.92. Following the sale, the senior vice president now owns 2,819 shares in the company, valued at $531,353.31. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Der Vaart Sandra D. Van also recently made the following trade(s):

  • On Monday, February 10th, Der Vaart Sandra D. Van sold 133 shares of Laboratory Corp. of America stock. The stock was sold at an average price of $181.99, for a total transaction of $24,204.67.

Shares of LH opened at $195.28 on Friday. The stock has a 50 day moving average price of $176.75 and a 200 day moving average price of $170.23. The company has a quick ratio of 1.08, a current ratio of 1.17 and a debt-to-equity ratio of 0.93. The company has a market capitalization of $18.91 billion, a price-to-earnings ratio of 23.36, a price-to-earnings-growth ratio of 1.92 and a beta of 1.07. Laboratory Corp. of America Holdings has a 52-week low of $140.53 and a 52-week high of $196.36.

Laboratory Corp. of America (NYSE:LH) last announced its quarterly earnings results on Thursday, February 13th. The medical research company reported $2.86 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.80 by $0.06. The firm had revenue of $3 billion during the quarter, compared to the consensus estimate of $2.92 billion. Laboratory Corp. of America had a return on equity of 15.59% and a net margin of 7.13%. The firm’s quarterly revenue was up 7.6% compared to the same quarter last year. During the same period in the prior year, the company posted $2.52 earnings per share. On average, equities analysts anticipate that Laboratory Corp. of America Holdings will post 11.94 EPS for the current fiscal year.

A number of analysts recently weighed in on the stock. Wells Fargo & Co assumed coverage on shares of Laboratory Corp. of America in a research note on Tuesday, January 7th. They set an “overweight” rating and a $210.00 target price on the stock. Bank of America lowered shares of Laboratory Corp. of America from a “neutral” rating to an “underperform” rating in a research note on Friday, January 3rd. Canaccord Genuity restated a “hold” rating and set a $170.00 target price on shares of Laboratory Corp. of America in a research note on Thursday, October 24th. Zacks Investment Research upgraded shares of Laboratory Corp. of America from a “sell” rating to a “hold” rating and set a $186.00 target price on the stock in a research note on Monday, January 13th. Finally, Citigroup upped their target price on shares of Laboratory Corp. of America from $179.00 to $204.00 and gave the stock a “neutral” rating in a research note on Friday. Three research analysts have rated the stock with a sell rating, four have given a hold rating and eight have given a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $193.19.

Institutional investors and hedge funds have recently made changes to their positions in the stock. Peddock Capital Advisors LLC acquired a new stake in shares of Laboratory Corp. of America in the fourth quarter valued at approximately $25,000. Financial Advantage Inc. acquired a new stake in shares of Laboratory Corp. of America in the third quarter valued at approximately $26,000. Rational Advisors LLC boosted its holdings in shares of Laboratory Corp. of America by 106.2% in the third quarter. Rational Advisors LLC now owns 200 shares of the medical research company’s stock valued at $34,000 after acquiring an additional 103 shares during the period. Orion Portfolio Solutions LLC acquired a new stake in shares of Laboratory Corp. of America in the fourth quarter valued at approximately $36,000. Finally, Usca Ria LLC acquired a new stake in shares of Laboratory Corp. of America in the third quarter valued at approximately $40,000. 90.74% of the stock is owned by hedge funds and other institutional investors.

Laboratory Corp. of America Company Profile

Laboratory Corporation of America Holdings operates as an independent clinical laboratory company worldwide. It operates in two segments, LabCorp Diagnostics (LCD) and Covance Drug Development. It offers various clinical laboratory tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, Pap tests, hemoglobin A1C and vitamin D products, prostate-specific antigens, tests for sexually-transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests.

Featured Story: Treasury Bonds

Insider Buying and Selling by Quarter for Laboratory Corp. of America (NYSE:LH)

Receive News & Ratings for Laboratory Corp. of America Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Corp. of America and related companies with MarketBeat.com's FREE daily email newsletter.